» Authors » Bachtiar Rifai Pratita Ihsan

Bachtiar Rifai Pratita Ihsan

Explore the profile of Bachtiar Rifai Pratita Ihsan including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 11
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Khasanah U, Nurrahmah Q, Amalia T, Putri Z, Imrokatul Mufidah , Napik R, et al.
J Ethnopharmacol . 2024 Apr; 330:118200. PMID: 38621467
Ethnopharmacological Relevance: Malaria eradication has been a major goal of the Indonesian government since 2020. Medicinal plants, such as Strychnos lucida R. Br., are empirically used to treat malaria through...
2.
Shalas A, Winarsih S, Pratita Ihsan B, Kharismawati A, Firdaus A, Wiloka E
Res Pharm Sci . 2023 Aug; 18(4):371-380. PMID: 37614619
Background And Purpose: The incidence of antibiotic resistance rapidly emerges over the globe. In the present study, the synthesis of thiourea derivatives as antibacterial agents and their biological evaluation are...
3.
Pisani E, Dewi A, Palagyi A, Praveen D, Pratita Ihsan B, Lawuningtyas Hariadini A, et al.
Am J Trop Med Hyg . 2023 May; 108(6):1287-1299. PMID: 37160275
Lower-middle income Indonesia, the world's fourth most populous country, has struggled to contain costs in its mandatory, single-payer public health insurance system since the system's inception in 2014. Public procurement...
4.
Dewi A, Pisani E, Pratita Ihsan B, Lawuningtyas Hariadini A, Patel A, Palagyi A, et al.
J Pharm Policy Pract . 2023 Mar; 16(1):50. PMID: 36949533
Background: In Indonesia, the world's fourth most populous country, cardiovascular diseases (CVDs) are a leading cause of death and disability. Government efforts to reduce the burden of CVD include a...
5.
Dewi A, Patel A, Palagyi A, Praveen D, Pratita Ihsan B, Lawuningtyas Hariadini A, et al.
BMJ Glob Health . 2022 Nov; 7(11). PMID: 36427901
Background: The WHO has warned that substandard and falsified medicines threaten health, especially in low and middle-income countries (LMICs). However, the magnitude of that threat for many medicines in different...